Stock Events

SOPHiA Genetics SA 

$4.6
6
-$0.19-3.97% Friday 20:30

Statistics

Day High
4.64
Day Low
4.35
52W High
7.37
52W Low
2.13
Volume
162,369
Avg. Volume
101,220
Mkt Cap
300.73M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

7MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.38
-0.25
-0.13
0
Expected EPS
-0.27
Actual EPS
-0.21

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SOPH. It's not an investment recommendation.
Alphabet
68145
GOOGL
Apple
60342
AAPL
Microsoft
56068
MSFT
Amazon
51638
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap16.63B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with SOPHiA Genetics' data-driven analysis.
Pacific Biosciences of California
PACB
Mkt Cap373.13M
Pacific Biosciences offers long-read sequencing technologies that compete with SOPHiA Genetics in the genomic analysis and clinical diagnostics market.
Guardant Health
GH
Mkt Cap3.53B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing with SOPHiA Genetics in the oncology diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap587.11M
Fulgent Genetics offers comprehensive genetic testing and competes with SOPHiA Genetics in the genetic analysis and diagnostics market.
Qiagen NV
QGEN
Mkt Cap9.38B
Bionano Genomics
BNGO
Mkt Cap45.33M
Bionano Genomics focuses on genomic analysis with its Saphyr system, competing in the structural variation analysis market alongside SOPHiA Genetics.
Exact Sciences
EXAS
Mkt Cap7.8B
Exact Sciences specializes in cancer diagnostics, including molecular screening tests, competing with SOPHiA Genetics in the molecular diagnostics market.
Thermo Fisher Scientific
TMO
Mkt Cap211.09B
Thermo Fisher Scientific offers a wide range of solutions for genetic analysis and diagnostics, making it a broad competitor to SOPHiA Genetics in the life sciences sector.
Intellia Therapeutics
NTLA
Mkt Cap2.16B
Intellia Therapeutics is involved in CRISPR gene editing, a technology that could compete with SOPHiA Genetics in the future of genetic diagnostics and therapeutics.

Analyst Ratings

7.33$Average Price Target
The highest estimate is $8.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Show more...
CEO
Employees
430
Country
CH
ISIN
CH1125843347
WKN
000A3CVT8

Listings

F
DE
90B.F
XNAS
US
SOPH